in the vicinity of King’s Cross, and that around 40 workers will be based at the site from Novo Nordisk’s R&D and IT divisions. The KQ cluster is in close proximity to major institutions at ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...